“America First” Wins Again: Swiss Pharma Giant Bows to Trump’s Leadership
President Donald Trump’s relentless push to revive American manufacturing scored another victory this week as Swiss pharmaceutical titan Novartis announced a historic $23 billion investment to build seven new U.S. facilities and expand three others. The move, detailed in Novartis’ press release, will create 1,000 high-skilled jobs at Novartis and 4,000 support roles across Florida, Texas, California, and other states. This comes just days after Trump vowed to impose “major tariffs” on foreign drug imports, proving yet again that his America First policies force global corporations to put American workers first.
“We’re going to tariff our pharmaceuticals—they’ll come rushing back to our country because we’re the big market.”
— President Donald Trump, National Republican Congressional Committee event, April 9, 2025
Novartis’ Surrender to Common Sense
Facing Trump’s promised tariffs, Novartis is scrambling to localize production of lifesaving drugs like heart failure treatment Entresto and cancer therapy Pluvicto. Key investments include:
- Two radioligand therapy plants in Florida and Texas to boost domestic cancer care
- A $1.1 billion biomedical research hub in San Diego
- Four undisclosed manufacturing sites for biologics and chemical drugs
- Expansions in Indiana, New Jersey, and California
As Reuters reported, Novartis CEO Vas Narasimhan admitted the tariffs “will be painful” but claimed they weren’t the “driving factor”—a laughable attempt to save face after Trump’s pressure left them no choice.
Trump’s Masterstroke: Turning Pharma Weakness Into Strength
For decades, America’s drug supply chain has been held hostage by China and Europe. As Trump noted in his April 2 tariff speech:
“We don’t make antibiotics here anymore. They’re all in China. Not anymore.”
Novartis’ surrender follows similar moves by Eli Lilly ($27 billion investment) and Johnson & Johnson ($55 billion expansion), proving Trump’s tariffs are the antidote to decades of globalization poison. The media’s fearmongering about “shortages” and “price hikes” (CNN, April 9) collapses under the weight of 5,000 new American jobs and 100% domestic production of Novartis’ key medicines.
Silencing the Deep State Doubters
While swamp creatures whine about “trade wars,” real patriots see the pattern:
- 2017-2020: Trump rebuilds military, unleashes energy dominance
- 2025: Trump 2.0 dismantles pharma outsourcing
The same bureaucrats who let China dominate PPE production during COVID are now attacking Trump’s drug tariffs. But as BBC reported, his 104% tariffs on China forced Novartis’ hand—exposing the globalist lie that America can’t compete.
The Blueprint for American Renewal
Novartis’ investment proves Trump’s formula works:
- Tariffs pressure foreign exploiters
- Tax cuts reward domestic investment
- Patriotism over profits
As the deep state media obsesses over fake “scandals,” Trump delivers real results: factories, jobs, and medical sovereignty. The era of begging China for antibiotics is over.
Stay vigilant with Golden Age Patriots: Follow us on X and Facebook to track how Trump’s America First agenda continues crushing the globalist elite.
